Graham Cooper Appointed Chief Financial Officer of Receptos

         Graham Cooper Appointed Chief Financial Officer of Receptos

PR Newswire

SAN DIEGO, Feb. 14, 2013

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that
Graham Cooper has been appointed Chief Financial Officer. Mr. Cooper joins the
company after serving as Chief Financial Officer of Geron Corporation and
Orexigen Therapeutics, Inc.

"Graham brings to Receptos tremendous strategic insight and financial
experience, including Orexigen's successful initial public offering," said
Faheem Hasnain, President and Chief Executive Officer of Receptos. "Graham
will play a key leadership role as we capitalize Receptos to execute on our
clinical development strategy. He joins us at a particularly exciting time,
having initiated the Phase 2 portion of our randomized Phase 2/3 study for
RPC1063, which has the potential to be the next S1P1R modulator to market in
relapsing multiple sclerosis."

Added Mr. Cooper, "I see a great deal of promise in Receptos' pipeline of
therapeutics as well as its skilled leadership team. Receptos is a fast-moving
company with a history of strong execution, and I look forward to our
evolution into a late-stage clinical development organization."

Cooper joins Receptos from Geron, where he served as EVP-Finance and Chief
Financial Officer. In this capacity, he led investor relations and financial
activities and served on the Executive Management Committee that oversaw
clinical, research, regulatory and financial activities. Prior to Geron, he
served as SVP-Finance and Chief Financial Officer of Orexigen from 2006 to
2012. During his tenure, Orexigen raised over $300 million in public and
private equity, including $80 million through an initial public offering.
Earlier in his career, he served as Director of healthcare banking for
Deutsche Bank and as a Senior Accountant for Deloitte & Touche, where he
earned his CPA. He received a Master's degree in Business Administration from
the Graduate School of Business at Stanford University and a Bachelor's degree
in Economics from the University of California, Berkeley.

About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for
the treatment of immune and metabolic diseases. The company's lead program,
RPC1063, is a potential best-in-class sphingosine 1-phosphate 1 receptor
(S1P1R) small molecule modulator for immune indications, including relapsing
multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is
currently enrolling patients into the randomized Phase 2 portion of a Phase
2/3 study examining the efficacy of RPC1063 in RMS and a randomized Phase 2
study examining the efficacy of RPC1063 in ulcerative colitis (UC). Receptos
has established expertise in high resolution protein crystal structure
determination, biology and drug discovery for G-protein-coupled receptors
(GPCRs). This expertise has formed the basis of collaborations with Eli Lilly
and Ono Pharmaceutical and a partnership with Janssen Pharmaceuticals, Inc.
For more information visit

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271

SOURCE Receptos, Inc.

Press spacebar to pause and continue. Press esc to stop.